MedTrace Logo

Safe Renal Function In Long Term Heart Transplanted Patients

NCT00505102 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-02-13

No results posted yet for this study

Summary

The purpose of this study is to verify whether the reduction of cyclosporine dosages associated with Everolimus administration may improve renal function as compared to patients maintained on standard immunosuppressive therapy

Conditions

Interventions

DRUG

Everolimus

cyclosporine dose reduced of 50% after introduction of everolimus

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    collaborator OTHER

  • A.O. Ospedale Papa Giovanni XXIII

    lead OTHER

Principal Investigators

  • Roberto Fiocchi, MD PhD · Heart Transplant Center Ospedali Riuniti Bergamo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505102 on ClinicalTrials.gov